Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Angela BelliniUlrike PötschgerVirginie BernardEve LapoubleSylvain BaulandePeter F AmbrosNathalie AugerKlaus BeiskeMarie BernkopfDavid R BettsJaydutt BhalshankarNick BownKatleen de PreterNathalie ClémentValérie CombaretJaime Font de MoraSally L GeorgeIrene JiménezMarta JeisonBarbara MarquesTommy MartinssonKatia MazzoccoMartina MoriniAnnick Mühlethaler-MottetRosa NogueraGaëlle PierronMaria RossingSabine Taschner-MandlNadine Van RoyAles VichaLouis CheslerWalentyna BalwierzVictoria CastelMartin ElliottPer KognerGeneviève LaureysRoberto LukschJosef MalisMaja Popovic-BeckShifra AshOlivier O DelattreDominique Valteau-CouanetDeborah A TweddleRuth Lydia LadensteinGudrun SchleiermacherPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations.